spacer
home > ict > spring 2018 > imaging innovations
PUBLICATIONS
International Clinical Trials

Imaging Innovations

In every clinical trial, data rules. In trials for treatments of solid cancerous tumours, much of that critical data relates to the size, type, and appearance of new lesions, whether used as eligibility criteria or as safety or efficacy endpoints. The importance of having clean, accurate measures and objective interpretations of those measures to the success of an oncology trial cannot be overstated.

Ensuring the validity of imaging data points in oncology trials is particularly challenging due to the complexity and variability in acquiring and assessing images. Protocols must set forth the choice of imaging modality, the image acquisition parameters, and the specific protocol for the IV contrast or oral contrast. This will enable the application of more than 10 different assessment criteria.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sophie Winandy is Product Manager at ERT and has more than 10 years of experience working closely with clinical trial sponsors and CROs to identify and implement optimal imaging approaches that accelerate the development of new medical products. Drawing on her training as a Registered Technologist, Magnetic Resonance Imaging, Sophie helped to develop the imaging solutions employed by researchers across hundreds of clinical trials during her tenure at Biomedical Systems (acquired by ERT in 2017).
spacer
Sophie Winandy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies win Cork Company of the Year

We’re very proud to announce that last Friday we won the Cork Company of the Year Award in the corporate category.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement